Condition category
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting

Contact information



Primary contact

Prof Penella Woll


Contact details

Weston Park Hospital
Whitham Road
S10 2SJ
United Kingdom

Additional identifiers

EudraCT number number


Protocol/serial number


Study information

Scientific title

Axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas: a phase II open-label parallel-group (non-randomised) study



Study hypothesis

The study objective is to evaluate the therapeutic activity, safety and tolerability of axitinib in patients with advanced/metastatic soft tissue sarcoma who have relapsed after standard chemotherapy. The therapeutic activity will be separately assessed in angiosarcoma, synovial sarcoma, leiomyosarcomas and other sarcomas.

On 24/02/2011 the overall trial end date was updated from 01/07/2011 to 31/08/2012.

Ethics approval

West Midlands REC on 15/12/2009

Study design

Phase II open-label non-randomised multi-centre parallel-group study

Primary study design


Secondary study design

Non randomised study

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Advanced angiosarcoma and other soft tissue sarcomas


All participants will receive the same treatment. However, they will be grouped according to the four pathological subtypes: angiosarcoma, synovial sarcoma, leiomyosarcoma and other (sarcoma, not otherwise specified [NOS]), and each group (stratum) will be analysed separately (parallel-group analysis).

Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3 mg twice daily. A four-week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.

Disease evaluation will be carried out 12 weeks after study entry (even if the study treatment has already been discontinued) then every 12 weeks until disease progression. After disease progression, patients should be followed up every 3 months for survival. Patients will be followed-up until death or the end of the trial. It is expected to complete accrual in 2 years and the study in 3 years.

Intervention type



Phase II

Drug names


Primary outcome measures

Proportion of patients progression-free 12 weeks after starting treatment, defined according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Secondary outcome measures

1. Tumour response rate (using RECIST criteria) at end of treatment
2. Time to progression, defined as the interval in whole days between the date of registration into the trial and the earliest date of detection of disease progression
3. Progression-free survival, defined as the interval in whole days between the date of registration into the trial and the earliest of date of detection of disease progression or date of death from any cause. For those patients who do not experience disease progression or die during the course of the trial, progression-free survival times will be censored at the last follow-up date.
4. Overall survival, defined as the interval in whole days between the date of registration into the trial and date of death from any cause; patients who do not die during the course of the trial will be censored at the last follow-up date.
5. Changes in performance status, assessed at screening, weekly during cycle 1, monthly from cycle 2 and at the end of treatment
6. Adverse events, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Report from date of patient enrolment into the study until 30 days after last exposure to the trial treatment.
7. Biomarkers of angiogenesis in blood and tumour biopsy samples. A paraffin-fixed block will be requested from relevant histopathology departments for the pathological and biological studies, for angiosarcomas only, fresh tumour material will be required. If not already available, a core biopsy will be required.

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Pathologically confirmed soft tissue sarcoma, including:
1.1. Angiosarcoma, including intermediate and malignant vascular tumours (World Health Organization [WHO] classification, 2002) and Kaposi's sarcoma
1.2. Leiomyosarcoma, including uterine, skin or non organ origin
1.3. Synovial sarcoma
1.4. Other eligible subtypes of soft tissue sarcoma of Trojani intermediate or high grade, including fibroblastic, fibrohistiocytic, adipocytic, rhabdomyosarcoma, malignant peripheral nerve sheath, and NOS. See exclusion criteria for ineligible subtypes
2. Locally advanced or metastatic disease incurable by surgery or radiotherapy
3. Measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria
4. Evidence of objective disease progression in the past 6 months, without anticancer treatment since progression
5. Patients ineligible for chemotherapy (e.g., through age, clinical condition or patient refusal) or who have received no more than two prior chemotherapy regimens
6. Both males and females, age >=16
7. WHO performance status 0, 1 or 2
8. At least 4 weeks from prior anticancer treatment (surgery, radiotherapy and systemic therapies) and full recovery from all their adverse effects
9. Adequate physiological function:
9.1. Renal : calculated or measured creatinine clearance >=50 ml/min
9.2. Haematological: absolute neutrophil count (ANC) >=1.5 x 109/L, platelets >=100 x 109/L, international normalised ratio (INR) <=1.2
9.3. Hepatic: bilirubin within normal range, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=3 x upper limit of normal
9.4. Cardiac: left ventricular ejection fraction (LVEF) (measured by echocardiography [ECHO] or multiple uptake gated acquisition scan [MUGA]) within normal range
10. Negative pregnancy test and agrees to comply with contraceptive measures
11. Able to swallow oral medication

Participant type


Age group




Target number of participants

Between 72 and 164

Participant exclusion criteria

Current exclusion criteria as of 18/10/2011:
1. Ineligible pathological subtypes including:
1.1. Osteosarcoma
1.2. Ewings/primitive neuroectodermal tumour (PNET) sarcomas
1.3. Chondrosarcoma
1.4. Gastrointestinal stromal tumours (GIST)
1.5. Dermatofibrosarcoma protuberans (DFSP)
1.6. Malignant mesothelioma
1.7. Mixed mesodermal tumours of uterus
2. Known central nervous system metastases
3. Age <16 years
4. Current use or anticipated need for treatment with drugs that are known CYP3A4 or CYP1A2 inducers (i.e. carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, primidone, rifabutin, rifampicin, and St. John's Wort)
5. Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors
6. Previous malignancies (except curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix or breast) within the past 3 years
7. Uncontrolled or poorly controlled hypertension: systolic blood pressure (BP) >=150 mmHg or diastolic BP >=90 mmHg. Hypertension may be treated prior to study entry, but 3 consecutive readings less than 150/90 must be obtained, at least 24 h apart prior to study entry
8. Heart failure >=NYHA class II
9. History within the previous 6 months of any blood clots in the sputum or streaky haemoptysis that was persistent (> 2 weeks) or recurrent (> 3 episodes).
10. Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, deep vein thrombosis or pulmonary embolism
11. Therapeutic dose warfarin. Low molecular weight heparin is permitted.
12. History of malabsorption or major gastrointestinal tract resection likely to affect study drug absorption
13. Pregnancy or breastfeeding. Female patients must be surgically sterile or be postmenopausal, or must agree to use two effective contraception measures during the period of therapy which should be continued for 4 weeks after the last dose of study therapy. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
Added 18/10/2011:
14. Regular treatment with antiplatelet medication, including aspirin >325 mg/day or NSAIDs.
15. Patients with cavitating lung metastases or any metatstasis abutting or invading a major pulmonary blood vessel on baseline CT or MRI scan.
16. History of bleeding diathesis or coagulopathy within 12 months of study entry.

Previous exclusion criteria:
9. History of hemoptysis >1/2 teaspoon (2.5 ml) of blood in any 24-hour period within prior 2 weeks of enrolment

Points 1-8 and 10-13 remained unchanged.

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Weston Park Hospital
S10 2SJ
United Kingdom

Sponsor information


Sheffield Teaching Hospitals NHS Foundation Trust (UK)

Sponsor details

Pegasus House
463a Glossop Road
S10 2QD
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

Cancer Research UK (UK) (ref: C5410/A10910)

Alternative name(s)


Funding Body Type

private sector organisation

Funding Body Subtype

other non-profit


United Kingdom

Funder name

Pfizer (USA) (supplementary funding)

Alternative name(s)

Pfizer Inc.

Funding Body Type

private sector organisation

Funding Body Subtype



United States of America

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes